From heart failure and kidney dysfunction to cardiorenal syndrome: TMAO may be a bridge
Frontiers in Pharmacology · 21.11.2023 · 14
DOI: 10.3389/fphar.2023.1291922 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 21.11.2023. Verfasst von Jialun Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, The Second Hospital of Jilin University, Changchun, Jilin, China. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 131 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Jilin Province Development and Reform Commission.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
The study of trimethylamine oxide (TMAO), a metabolite of gut microbiota, and heart failure and chronic kidney disease has made preliminary achievements and been summarized by many researchers, but its research in the field of cardiorenal syndrome is just beginning. TMAO is derived from the trimethylamine (TMA) that is produced by the gut microbiota after consumption of carnitine and choline and is then transformed by flavin-containing monooxygenase (FMO) in the liver. Numerous research results have shown that TMAO not only participates in the pathophysiological progression of heart and renal diseases but also significantly affects outcomes in chronic heart failure (CHF) and chronic kidney disease (CKD), besides influencing the general health of populations. Elevated circulating TMAO levels are associated with adverse cardiovascular events such as HF, myocardial infarction, and stroke, patients with CKD have a poor prognosis as well. However, no study has confirmed an association between TMAO and cardiorenal syndrome (CRS). As a syndrome in which heart and kidney diseases intersect, CRS is often overlooked by clinicians. Here, we summarize the research on TMAO in HF and kidney disease and review the existing biomarkers of CRS. At the same time, we introduced the relationship between exercise and gut microbiota, and appropriately explored the possible mechanisms by which exercise affects gut microbiota. Finally, we discuss whether TMAO can serve as a biomarker of CRS, with the aim of providing new strategies for the detection, prognostic, and treatment evaluation of CRS.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, The Second Hospital of Jilin University, Changchun, Jilin, China.
- China-Japan Union Hospital of Jilin University, Changchun, Jilin, China.
Förderung
- Jilin Province Development and Reform Commission
Zitieren
APA
Zhang, J., Zhu, P., Li, S., Gao, Y., & Xing, Y. (2023). From heart failure and kidney dysfunction to cardiorenal syndrome: TMAO may be a bridge. Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1291922
Vancouver
Zhang J, Zhu P, Li S, Gao Y, Xing Y. From heart failure and kidney dysfunction to cardiorenal syndrome: TMAO may be a bridge. Frontiers in Pharmacology. 2023;14. doi:10.3389/fphar.2023.1291922
BibTeX
@article{Zhang2023,
author = {Zhang, Jialun and Zhu, Peining and Li, Siyu and Gao, Yufei and Xing, Yue},
title = {From heart failure and kidney dysfunction to cardiorenal syndrome: TMAO may be a bridge},
journal = {Frontiers in Pharmacology},
year = {2023},
volume = {14},
doi = {10.3389/fphar.2023.1291922}
}
EUVIMED